Q4 2020 13F Holders as of 31 Dec 2020
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
125,981,648
-
Total 13F shares
-
63,890,305
-
Share change
-
-264,042
-
Total reported value
-
$3,654,164,157
-
Put/Call ratio
-
57%
-
Price per share
-
$57.20
-
Number of holders
-
165
-
Value change
-
-$7,921,158
-
Number of buys
-
80
-
Number of sells
-
71
Institutional Holders of Apellis Pharmaceuticals, Inc. - Common Stock (APLS) as of Q4 2020
As of 31 Dec 2020,
Apellis Pharmaceuticals, Inc. - Common Stock (APLS) was held by
165 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
63,890,305 shares.
The largest 10 holders included
WELLINGTON MANAGEMENT GROUP LLP, BlackRock Inc., VANGUARD GROUP INC, HILLHOUSE CAPITAL ADVISORS, LTD., PRICE T ROWE ASSOCIATES INC /MD/, JENNISON ASSOCIATES LLC, STATE STREET CORP, FARALLON CAPITAL MANAGEMENT LLC, VICTORY CAPITAL MANAGEMENT INC, and Cormorant Asset Management, LP.
This page lists
165
institutional shareholders reporting positions in this security
for the Q4 2020 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.